Search

Invizius - H-Guard against inflammation

Despite improvements in dialysis therapy, cardiovascular disease remains the leading cause of death for almost half of all dialysis patients and life expectancy on dialysis is just one-third of that for the general population.

Invizius awarded major funding to bring dialysis treatment to clinic
Invizius wins second Biomedical Catalyst Grant to take H-Guard into new field